The global subcutaneous biologics market generated $99 billion in 2017 and is expected to grow to $171 billion by the year 2025, experiencing a CAGR of 11.5 percent in the forecast period of 2017 to 2024, according to the findings of a new report from device manufacturing firm, nGageIT.
Subcutaneous delivery of biologics is a rapidly growing market that is gaining substantial attention from researchers and manufacturers worldwide. Biologics currently own a 25 percent share of the overall pharmaceutical market.
However, most therapies in the biologics market were designed for intravenous administration, which require a clinical setting for dosing and have a high overall development and treatment cost. As a result, the subcutaneous route of administration has emerged as a promising approach for the delivery of biologics.
Products in the subcutaneous biologics market offers numerous advantages over other routes of delivery, including reduction in time spent in drug adminstration, reduced patient time at healthcare facilities, decreased healthcare costs and improved therapy compliance. As a result, several approved therapeutics that can only be delivered intraveneously are currently in the process of being reformulated and evaluated for subcutaneous administration.
The subcutaneous biologics route of drug administration is highly effective for the administration of biologics such as vaccines, proteins, antibodies, peptides and other large and complex molecules through the use of large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants.
The utility of viscous biologics in the treatment of chronic diseases, the increasing trend of self-medication and requirement of high concentration subcutaneous formulation of biologics are all factors driving the growth of the subcutaneous biologics market.
The subcutaneous biologics market is segmented based on drug delivery system and application. Based on drug delivery system, the market is categorized into prefilled syringes, wearable injectors, auto-injectors and drug reconstitution delivery systems. Depending on application, the market is divided into Crohn’s disease, rheumatoid arthritis, breast cancer, leukemia, lymphoma and psoriasis.
In terms of geography, there is huge healthcare spending and a high prevalence of rheumatoid arthritis and breast cancer in countries such as the United States and Canada. Five countries in Europe (Germany, France, United Kingdom, Italy and Spain) show the greatest potential for market growth, while a convenient drug delivery format is in high demand in developing regions such as Asia Pacific and Latin America, Coherent Market Insights reports.
